Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Commissioner Marty Makary on Monday denied recent reports suggesting plans for his agency to add a black box warning onto ...

Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Now in 2025, the TGA has registered Pfizer's LP.8.1 vaccine, designed specifically to target the spike protein of LP.8.1.

The COVID-19 vaccines developed for the 2024-2025 respiratory disease season were around 75% effective at preventing ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...